Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRUSTS trial of trabectedin versus doxorubicin in untreated advanced soft tissue sarcoma
2009-014889-26Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Mar 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trabectedin and doxorubicin in soft tissue sarcoma (STS) (3 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Progression-free survival and Treatment safety. Started Mar 2011; status: completed.
02
Drugs
trabectedindoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2009-014889-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014889-26.